Nov. 20 at 12:19 PM
$RXRX $6.39 bid. DAC (dollar average cost)
$6.50 (8.8.24). EXIT
$10.00.
RETAIN POSITION.
UPDATE: The business combination of Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq:
$EXAI) ceased trading and will be delisted from Nasdaq.
“I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over
$450M in upfront and realized milestone payments received from partners to date out of more than
$20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.”
